Gink­go BioWorks picks up an­tibi­otics ef­fort with Roche where Warp Dri­ve Bio left off

When Rev­o­lu­tion Med­i­cines ab­sorbed fel­low Third Rock start­up Warp Dri­ve Bio in­to its op­er­a­tions last Oc­to­ber — then new­ly tran­si­tioned from an­ti­fun­gal to on­col­o­gy — the ex­ec team was still re­view­ing op­tions for the genome min­ing plat­form, which was the sub­ject of a deal with Roche.

They found a buy­er in Gink­go BioWorks, a spe­cial­ist in en­gi­neer­ing cus­tomized mi­crobes that has so far fo­cused on food and agri­cul­ture. The Boston-based com­pa­ny plans to in­te­grate Warp Dri­ve’s data­base of mi­cro­bial genome, as well as its search en­gine, with its own tech in pur­suit of new class­es of an­tibi­otics. Fi­nan­cials were not dis­closed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER